Who Supplies Rosuvastatin to India from BRAZIL

Importing finished pharmaceutical formulations containing Rosuvastatin into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs be registered and accompanied by an import license. The registration process involves submitting Form 40/41 to CDSCO, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Free Sale Certificate, and stability data. The import license is issued by the Directorate General of Foreign Trade (DGFT) upon approval from CDSCO. The timeline for obtaining these approvals can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory workload. For Rosuvastatin formulations under HS Code 30049099, specific requirements include demonstrating the drug's safety, efficacy, and quality, as well as compliance with Indian Pharmacopoeia standards.

Imported Rosuvastatin formulations must undergo quality testing at CDSCO-approved laboratories to ensure they meet Indian standards. Batch-wise testing is mandatory, with each batch requiring a Certificate of Analysis (CoA) that includes stability data, preferably in accordance with ICH Zone IV guidelines. The formulations must comply with the Indian Pharmacopoeia standards. Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity of the documents and the quality of the products. If a batch fails the quality tests, it may be rejected, leading to potential delays or the need for re-exportation.

In April 2025, the CDSCO introduced new regulations requiring import registration and licenses for all imported medicines, including finished formulations containing Rosuvastatin. This move aims to prevent the sale of unapproved or illegal medicines in the Indian market. The regulations stipulate that drugs manufactured in Special Economic Zones (SEZs) for export purposes are not permitted for transfer to the Domestic Tariff Area (DTA) for sale and distribution. Additionally, the Production-Linked Incentive (PLI) scheme, introduced to boost domestic manufacturing, may impact the import of finished formulations by encouraging local production. These policy changes are expected to affect the import dynamics of Rosuvastatin formulations from Brazil to India.

India imports finished Rosuvastatin formulations to meet the demand for branded and patented products, as well as specific dosage forms not produced domestically. The market size for Rosuvastatin in India is substantial, with a total export market of $463.3 million across 427 exporters to 143 countries. This indicates a significant domestic demand for Rosuvastatin formulations, which is partially met through imports.

The Basic Customs Duty (BCD) on Rosuvastatin formulations under HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable, along with a Social Welfare Surcharge (SWS) of 10%. This results in a total landed duty of approximately 17.10%. There are no additional duties such as Anti-Dumping Duty (ADD) or Countervailing Duty (CVD) imposed on these imports.

India sources Rosuvastatin formulations from Brazil due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Brazil's pharmaceutical industry is known for its compliance with international quality standards, making it a competitive supplier. Other suppliers include China, Germany, and the United States; however, Brazil's share in the Indian market is notable due to these advantages.

India imports Rosuvastatin formulations from Brazil due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Brazil's pharmaceutical industry complies with international quality standards, making it a competitive supplier. Specific formulations and dosage forms not produced domestically are sourced from Brazil to meet market demand.

Compared to other origins like China, the European Union, and the United States, Brazil offers competitive pricing, high-quality products, and reliable supply chains. Brazil's unique advantage lies in its compliance with international quality standards and the availability of specific formulations not produced elsewhere.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal, but importers should remain vigilant and consider diversifying suppliers to mitigate risks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with quality standards.
5. 5Regulatory Compliance: Stay updated on regulatory changes and ensure all imports meet CDSCO requirements.

1. 1Obtain a valid Importer Exporter Code (IEC) from DGFT.
2. 2Register the product with CDSCO by submitting Form 40/41.
3. 3Secure an import license from DGFT upon CDSCO approval.
4. 4Ensure compliance with all regulatory requirements under the Drugs and Cosmetics Act.
5. 5Engage a licensed customs broker for clearance procedures.
6. 6Seek an advance ruling for HS Code 30049099 if necessary.